Regulatory Strategic Guidance

Freyr offers comprehensive Health Canada Regulatory strategic guidance for generic drug manufacturers, ensuring compliance with ANDS requirements. Our expertise covers submission planning, risk mitigation, and post-approval strategies to streamline the registration process and optimize market entry timelines.

Regulatory Strategic Guidance - Overview

Generic manufacturers face challenges such as understanding the complexity of Canada’s drug registration guidelines for generic drug approval through an Abbreviated New Drug Submission (ANDS) and complying with the respective guidelines. To overcome them, manufacturers must adopt a robust approach for different types of medicinal products and ensure timely registration and approvals.

Health Canada’s Regulatory strategic guidance involves setting up the right Regulatory roadmap during product development and studies to be performed specific to the dosage form/indication. The submission strategy shall guide the submission timelines, documents/data required for submission, and the approval process.

Without understanding Canada’s drug registration guidelines, manufacturers may face delays in product registration, which can affect costs and go-to-market timelines. Therefore, Freyr provides clients with accurate Health Canada’s Regulatory strategic guidance for registering generic medicinal products under Health Canada’s guidance documents, backed up with Regulatory intelligence reports.

Regulatory Strategic Guidance - Expertise

  • Planned submission of generic drug applications as per Canada’s drug registration guidelines.
  • Evaluate the latest Health Canada’s Regulatory strategic guidance and provide appropriate support.
  • Strategic guidance on day-to-day manufacturing and development activities to design the specification and protocols/reports.
  • Guidance in preparation of the pre-submission meeting packages.
  • Identification of the possible risks and preparation of risk-mitigation strategies before Health Canada Regulatory submission.
  • Regulatory submission strategy for post-approval change submissions.
  • Preparation of the response submission strategy for HA queries.
  • Regulatory strategy preparation for the expedited review and approval of priority drugs.
  • Strategic guidance on planning in the submission of stability and bioequivalence studies.
  • Evaluation to determine the legal status of the medicinal product.
Regulatory Strategic Guidance

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​